Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Kriegsmann, Katharina [VerfasserIn]   i
 Rieger, Michael [VerfasserIn]   i
 Schwarzbich, Mark-Alexander [VerfasserIn]   i
 Sitter, Sören [VerfasserIn]   i
 Kriegsmann, Mark [VerfasserIn]   i
 Bruckner, Thomas [VerfasserIn]   i
 Hensel, Manfred [VerfasserIn]   i
 Ho, Anthony Dick [VerfasserIn]   i
 Witzens-Harig, Mathias [VerfasserIn]   i
 Wuchter, Patrick [VerfasserIn]   i
Titel:Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma
Verf.angabe:Katharina Kriegsmann, Michael Rieger, Mark-Alexander Schwarzbich, Sören Sitter, Mark Kriegsmann, Thomas Bruckner, Manfred Hensel, Anthony Dick Ho, Mathias Witzens‐Harig, Patrick Wuchter
E-Jahr:2018
Jahr:25 March 2018
Umfang:9 S.
Fussnoten:Gesehen am 29.10.2019
Titel Quelle:Enthalten in: European journal of haematology
Ort Quelle:Oxford : Wiley-Blackwell, 1987
Jahr Quelle:2018
Band/Heft Quelle:101(2018), 1, Seite 12-20
ISSN Quelle:1600-0609
Abstract:Objective For more than two decades, high-dose chemotherapy (HDT) and autologous blood stem cell transplantation (ABSCT) were treatment options for patients with aggressive B-cell non-Hodgkin's lymphoma (B-NHL). However, the ideal timing and the collective patient benefits are still being debated. Method We retrospectively analyzed the data of 163 patients with B-NHL who received an HDT protocol followed by ABSCT between 2001 and 2007. Patients were analyzed according to the time point of HDT/ABSCT to compare upfront (directly after induction, n = 72, 44%) versus secondary transplantation (at first relapse, n = 91, 56%). Results The overall response rate was 100% and 94% after upfront and secondary HDT/ABSCT, respectively. No significant differences were found for hematopoietic recovery and toxicity profile. The progression-free survival (PFS) and overall survival (OS) probability were found to be significantly higher in the upfront HDT/ABSCT treatment group (P = .018 and P = .004). In multivariate analysis, upfront HDT/ABSCT and low IPI risk score had a significant beneficial effect on OS (P = .031 and P = .019). Conclusion HDT and ABSCT directly after induction chemotherapy were confirmed to be feasible with high PFS and OS rates. In addition, for patients with relapse after first-line therapy and consecutively poor prognosis, HDT/ABSCT also offers an effective treatment strategy.
DOI:doi:10.1111/ejh.13064
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1111/ejh.13064
 Verlag: https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13064
 DOI: https://doi.org/10.1111/ejh.13064
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:non-Hodgkin's lymphoma
 transplantation
K10plus-PPN:1680573179
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68447585   QR-Code
zum Seitenanfang